Johnson Pharmacare (532154) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
18 Nov, 2025Executive summary
Board approved unaudited financial results for the quarter and half year ended September 30, 2025.
Financial results were reviewed by the Audit Committee and received a limited review from statutory auditors.
Financial highlights
Total income from operations for the quarter and half year ended September 30, 2025, was nil.
Net loss for the quarter ended September 30, 2025, was ₹0.34 lakhs; for the half year, net loss was ₹5.68 lakhs.
Basic and diluted EPS for the quarter and half year were both ₹(0.00).
Paid-up equity share capital stood at ₹5,500 lakhs as of September 30, 2025.
Key financial ratios and metrics
Other equity as of September 30, 2025, was ₹116.91 lakhs.
Total assets as of September 30, 2025, were ₹5,836.76 lakhs.
Net cash flow from operating activities for the half year was ₹48.33 lakhs.
Cash and cash equivalents at period end were ₹3.11 lakhs.
Latest events from Johnson Pharmacare
- Net loss increased to ₹110.31 lakhs on flat revenue, with EPS at ₹(0.02) for the quarter.532154
Q1 26/27 - FY26 saw a sharp net loss, negative cash flows, and major doubts about financial viability.532154Q4 25/26
- New auditor and independent director appointed, with all regulatory confirmations in place.532154Q3 25/26
- Net loss narrowed for Q2 and H1 FY25, with negligible revenue and stable equity.532154Q2 24/25
- Net loss of ₹3.99 lakhs on revenue of ₹3.99 lakhs reported for Q1 FY25.532154Q1 24/25
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/25
- Net loss increased to Rs. 5.34 lakhs for Q1 FY26 as income declined and expenses rose.532154Q1 25/26
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/25